JATENZO: payments to doctors
Payments that named JATENZO as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.9M
- Providers
- 13,345
- Transactions
- 66,293
- Average per transaction
- $29
The per-transaction average — $29 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 13,345 providers the average total is $145, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Clarus Therapeutics Inc. | $1,451,293 | 75.0% |
| Tolmar, Inc. | $482,872 | 24.9% |
| Tolmar Pharmaceuticals, Inc. | $1,560 | 0.1% |